Executive Wealth Management LLC Sells 249 Shares of PRA Health Sciences Inc (PRAH)

Executive Wealth Management LLC reduced its holdings in shares of PRA Health Sciences Inc (NASDAQ:PRAH) by 2.5% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 9,520 shares of the medical research company’s stock after selling 249 shares during the quarter. Executive Wealth Management LLC’s holdings in PRA Health Sciences were worth $1,050,000 as of its most recent filing with the SEC.

Several other large investors have also added to or reduced their stakes in PRAH. Securian Asset Management Inc raised its stake in PRA Health Sciences by 1.4% during the 4th quarter. Securian Asset Management Inc now owns 7,171 shares of the medical research company’s stock valued at $659,000 after acquiring an additional 100 shares during the last quarter. Carroll Financial Associates Inc. raised its stake in PRA Health Sciences by 7.6% during the 1st quarter. Carroll Financial Associates Inc. now owns 1,517 shares of the medical research company’s stock valued at $167,000 after acquiring an additional 107 shares during the last quarter. BB&T Securities LLC raised its stake in PRA Health Sciences by 3.5% during the 4th quarter. BB&T Securities LLC now owns 4,240 shares of the medical research company’s stock valued at $389,000 after acquiring an additional 145 shares during the last quarter. D.A. Davidson & CO. raised its stake in PRA Health Sciences by 5.7% during the 4th quarter. D.A. Davidson & CO. now owns 2,698 shares of the medical research company’s stock valued at $248,000 after acquiring an additional 146 shares during the last quarter. Finally, State of Alaska Department of Revenue raised its stake in shares of PRA Health Sciences by 2.1% during the 4th quarter. State of Alaska Department of Revenue now owns 7,134 shares of the medical research company’s stock worth $656,000 after buying an additional 150 shares in the last quarter. 99.44% of the stock is owned by institutional investors and hedge funds.

Shares of PRAH stock traded up $0.15 during mid-day trading on Wednesday, hitting $87.53. 353,937 shares of the company’s stock were exchanged, compared to its average volume of 529,944. The company has a quick ratio of 0.90, a current ratio of 0.90 and a debt-to-equity ratio of 0.97. The stock has a market capitalization of $5.85 billion, a price-to-earnings ratio of 22.27, a price-to-earnings-growth ratio of 1.20 and a beta of 1.01. PRA Health Sciences Inc has a fifty-two week low of $82.12 and a fifty-two week high of $121.98.

PRA Health Sciences (NASDAQ:PRAH) last issued its earnings results on Wednesday, February 27th. The medical research company reported $1.21 earnings per share for the quarter, topping the consensus estimate of $1.18 by $0.03. The business had revenue of $729.65 million for the quarter, compared to analyst estimates of $750.67 million. PRA Health Sciences had a return on equity of 26.87% and a net margin of 5.50%. As a group, analysts anticipate that PRA Health Sciences Inc will post 4.63 earnings per share for the current fiscal year.

A number of equities analysts have recently issued reports on the company. Robert W. Baird increased their target price on PRA Health Sciences from $119.00 to $122.00 and gave the stock an “outperform” rating in a research note on Thursday, February 28th. BidaskClub upgraded PRA Health Sciences from a “buy” rating to a “strong-buy” rating in a report on Thursday, February 14th. Wolfe Research began coverage on PRA Health Sciences in a report on Tuesday, April 2nd. They issued a “market perform” rating on the stock. SunTrust Banks upped their price target on PRA Health Sciences to $120.00 and gave the stock an “average” rating in a report on Monday, March 4th. Finally, ValuEngine upgraded PRA Health Sciences from a “hold” rating to a “buy” rating in a report on Monday, February 4th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and five have given a buy rating to the stock. PRA Health Sciences has an average rating of “Hold” and a consensus price target of $113.22.

TRADEMARK VIOLATION NOTICE: This report was published by Sundance Herald and is the sole property of of Sundance Herald. If you are viewing this report on another publication, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this report can be read at https://sundanceherald.com/2019/05/29/executive-wealth-management-llc-reduces-stake-in-pra-health-sciences-inc-prah.html.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

See Also: Bollinger Bands

Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply